EUROAPI has undertaken several initiatives to increase its production capacities for several active pharmaceutical ingredients (APIs) listed as essential medicines by the French authorities.
 
EUROAPI’s Francopia subsidiary dedicated to controlled substances, will invest in R&D activities at its Vertolaye (Puy-de-Dôme) site to increase EUROAPI’s production of morphine and its derivatives, as well as their antagonists used as antidotes, by 2027.
 
At the plant extraction stage, the Group aims to develop an innovative process that could increase productivity between 20% and 30% and shorten industrial cycle time to help build up strategic stocks. At the chemical synthesis stage, EUROAPI plans to invest in more flexible technologies and equipment that would enhance production capacity by 15% to 20%.
 
EUROAPI plans further investments to increase its production capacity with total investments that could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026. 
 
As part of the Important Project of Common European Interest (IPCEI) currently under review by the European Commission, EUROAPI has presented projects to help cover the need for currently imported critical medicines such as macrolide antibiotics and corticosteroids, by 2030.
 
For corticosteroids (including methylprednisolone) used for their anti-inflammatory and immunosuppressive effects, EUROAPI’s aims to develop state-of-the-art processes and technologies at the Vertolaye site.
 
For macrolide antibiotics, the project to relaunch production would be deployed at the Saint-Aubin-lès-Elbeuf (Seine-Maritime) site and would enable EUROAPI to expand its portfolio in this global market.